Page 385 - The Vasculitides, Volume 1: General Considerations and Systemic Vasculitis

Ophthalmologic and Neuro-Ophthalmologic Aspects of Vasculitides 359

[3] Jennette JC, Falk RJ, Bacon PA. 2012 Revised international Chapel Hill consensus
conference nomenclature of vasculitides. Arthritis Rheum. 2013; 65:1-11.

[4] Ozen S, Ruperto N, Dillon MJ, et al. EULAR/PRES endorsed consensus criteria for the
classification of childhood vasculitides. Ann. Rheum. Dis., 2006; 65:936-941.

[5] Ruperto N, Ozen S, Pistorio A, et al. EULAR/PINTO/PRES criteria for Henoch-
Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis
and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and
clinical characterization. Ann. Rheum. Dis., 2010; 69:790-797.

[6] Salvarani C, Gabriel SE, O?Fallon WM, et al. The incidence of giant cell arteritis in
Olmsted, County, Minnesota: apparent fluctuations in a cyclic pattern. Ann. Intern.
Med., 1995; 123:192-194.

[7] Baldursson O, Steinsson K, Björnsson J, et al. Giant cell arteritis in Iceland. An
epidemiologic and histopathologic analysis. Arthritis Rheum. 1994, 37:1007-1012.

[8] Weyand CM, Liao YJ, Goronzy JJ. The immunopathology of giant cell arteritis:
diagnostic and therapeutic implications. J. Neuroophthalmol., 2012; 32:259-265.

[9] Gonzalez-Gay MA, Blanco R, Rodriguez-Valverde V, et al. Permanent visual loss and
cerebrovascular accidents in giant cell arteritis: predictors and response to treatment.
Arthritis Rheum. 1998; 41:1497-1504.

[10] Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology
1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;
33:1122-1128.

[11] Rao JK, Allen NB, Pincus T. Limitations of the 1990 American College of
Rheumatology classification criteria in the diagnosis of vasculitis. Ann. Intern. Med.,
1990; 129:345-352.

[12] Weyand CM, Goronzy JJ. Medium-and large-vessel vasculitis. N Engl J Med 2003;
349:160-169.

[13] Fraser JA, Weyand CM, Newman NJ, et al. The treatment of giant cell arteritis. Rev.
Neurol. Dis., 2008; 5:140-152.

[14] Hayreh SS, Podhajsky P, Zimmerman B. Ocular manifestations of giant cell arteritis.
Am. J. Ophthalmol., 1998; 125:509-520.

[15] Huston KA, Hunder GG, Lie JT, et al. Temporal arteritis: a 25-year epidemiologic,
clinical, and pathologic study. Ann. Intern. Med., 1978; 88:162-167.

[16] Nuenninghoff DM, Hunder GG, Christianson TJ, et al. Incidence and predictors of
large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery
stenosis) in patients with giant cell arteritis. Arthritis Rheum. 2003; 48:3532-3537.

[17] Hayreh SS, Podhajsky PA, Zimmerman B. Occult giant cell arteritis: ocular
manifestations. Am. J. Ophthalmol., 1998; 125:521–526.

[18] Prieto-González S, Arguis P, García-Martínez A, et al. Large vessel involvement in
biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients
using CT angiography. Ann. Rheum. Dis., 2012; 71:1170–1176.

[19] Guyer DR, Miller NR, Auer Cl, et al. The risk of cerebrovascular and cardiovascular
disease in patients with anterior ischemic optic neuropathy. Arch. Ophthalmol., 1985;
103:1136-1142.

[20] Hayreh SS. Anterior ischaemic optic neuropathy. Differentiation of arteritic from non-
arteritic type and its management. Eye, 1990; 4:25-41.

Complimentary Contributor Copy